Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Benjamin Anderson MD, FACS
Benjamin O. Anderson MD, FACS Advisory Board
Oliver Sartor MD
Oliver Sartor MD Advisory Board
Rafael Fonseca MD
Rafael Fonseca MD Editor-in-Chief
See All Experts
Published in Oncology

News · February 19, 2020

ASCO GU 2020: Pembrolizumab + Olaparib Continues to Show Promise in Molecularly Unselected Metastatic Castrate-Resistant Prostate Cancer

Patients had been pretreated with docetaxel and had also received hormone therapy.

PracticeUpdate Editorial Team

 

 Save  Recommend
 Share

Further Reading

Most Read This Week

Recently Updated